Skip to main content
. 2021 Mar 8;106(7):2021–2035. doi: 10.1210/clinem/dgab145

Table 1.

Baseline and changes over 12 months in clinical characteristics, body composition and biochemical parameters

Baseline measures Within group change over 12 months [mean (95% confidence interval)] P-value comparing changes between groups over 12 months
AN-IGF-1− (n = 37) AN-IGF-1+ (n = 38) AN-IGF-1− (n = 21) AN-IGF-1+ (n = 12)
Clinical characteristics
 Age (years) 19.4 ± 0.4 19.4 ± 0.3
 Bone age (years) 18.0 (16.6 to 18.0) 18.0 (16.3 to 18.0)
 Height (cm) 165.9 ± 1.0 163.1 ± 0.9a 0.1 (−0.3, 0.4) 0.8 (−0.0, 1.5) 0.061
 Race (% white /% African American /% more than 1 race) 89.2/0.0/10.8 89.5/2.6/7.9
 Ethnicity (% non-Hispanic/% Hispanic) 89.2/10.8 97.4/2.6
 Weight (kg) 51.4 ± 0.9 49.7 ± 0.8 3.1 (1.0, 5.1) 1.7 (−1.5, 4.9) 0.627
 BMI (kg/m2) 18.7 ± 0.3 18.7 ± 0.3 1.1 (0.3, 1.9) 0.5 (−0.8, 1.7) 0.562
 BMI Z-Score −0.92 (−1.54 to −0.56) −0.96 (−1.81 to −0.54) 0.45 (0.07, 0.83) −0.02 (−0.67, 0.63) 0.489
 % median BMI for age 87.4 ± 1.4 87.2 ± 1.2 4.6 (0.8, 8.4) 1.6 (−4.1, 7.2) 0.562
 Age of menarche (years) 13.0 (12.0 to 14.0) 13.0 (12.0 to 14.0)
 Duration of amenorrhea (months) 4.00 (0.00 to 11.50) 3.00 (0.00 to 8.50)
 Weight-bearing exercise activity (hours per week) 3.33 (1.52 to 6.47) 3.65 (1.23 to 6.45) 0.16 (−4.38, 4.69) −2.90 (−7.59, 1.80) 0.669
DXA measures of body composition
 Lean mass (kg) 37.5 ± 0.6 36.7 ± 0.6 1.5 (0.5, 2.5) 0.6 (−0.5, 1.6) 0.185
 Lean mass (%) 71.9 ± 0.9 72.0 ± 0.8 −2.0 (−4.3, 0.2) −0.2 (−3.3, 2.9) 0.307
 Fat mass (kg) 13.1 ± 0.6 12.7 ± 0.5 2.0 (0.3, 3.6) 0.9 (−1.6, 3.4) 0.464
 Fat mass (%) 24.6 ± 0.9 24.6 ± 0.8 2.1 (−0.2, 4.5) 0.2 (−3.1, 3.5) 0.319
Biochemical parameters
 25(OH) vitamin D (ng/mL) 33.0 (27.5 to 45.3) 30.5 (24.4 to 39.5) 6.7 (12.6,1.3) −0.6 (−8.3, 7.0) 0.082
 Calcium (mg/dL) 9.44 ± 0.05 9.42 ± 0.07 −0.16 (−0.34, 0.03) 0.19 (−0.24, 0.63) 0.111
 Phosphorus (mg/dL) 4.09 ± 0.08 4.01 ± 0.08 −0.26 (−0.51, 0.00) −0.25 (−0.90, 0.39) 0.878
 IGF-1 (ng/mL) 266.8 ± 14.3 249.7 ± 15.3 −32.9 (−67.4, 1.7) 101.9 (11.3, 192.5) 0.004
 IGF-1 Z-score −0.1 (−1.0 to 0.4) −0.3 (−1.0 to 0.2) −0.1 (−0.5, 0.3) 1.1 (0.1, 2.0) 0.019
 IGF-BP3 (ng/mL) 5073.7 ± 172.3 4988.5 ± 172.2 517.0 (625.0,408.9) −251.9 (−1045.3, 541.5) 0.441
 IGF-1/IGF-BP3 0.054 (0.041 to 0.062) 0.053 (0.037 to 0.063) −0.002 (−0.009, 0.006) 0.030 (0.003, 0.057) 0.011
 P1NP (μg/L) 86.7 (63.3 to 131.7) 98.7 (62.5 to 147.5) −12.1 (−33.4, 9.3) −39.5 (−89.2, 10.1) 0.280
 NTX (nM BCE) 14.5 (10.8 to 19.1) 15.4 (10.5 to 19.8) −3.5 (−6.8, −0.1) −1.0 (−7.7, 5.6) 0.167
 PTH (pg/mL) 21.5 ± 9.2 17.4 ± 1.7 −0.2 (−5.9, 5.4) 10.6 (2.9, 18.2) 0.021

Baseline data are presented as mean ± standard error of the mean or median (interquartile range); changes over 12 months are presented as mean (95% confidence interval). Bolded change over 12 months denotes significant within-group difference.

Abbreviations: BCE, bone collagen equivalents; IGF-1, insulin like growth factor-1, IGFBP-3: insulin like growth factor binding protein 3; NTX: N-telopeptide; P1NP: N-terminal propeptide of type 1 procollagen; PTH: parathyroid hormone

a Denotes significant baseline between-group difference.